# NIMBUS (NCT03789110)

> NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab
- Indication: hypermutated HER2-negative metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03789110
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer
- Interventions: Nivolumab; Ipilimumab
- Enrollment: 30
- Primary outcome: Overall Response Rate of Nivolumab in Combination With Ipilimumab

## Indexed commentary on NIMBUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 8
- X threads: 7
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nimbus-nct03789110

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03789110", "email": "<work email>"}; the inbox owner confirms by the emailed link.